http://www.law360.com/ Latest articles for organization: Dr. Reddy's Copyright 2009 Portfolio Media, Inc. en-US http://www.law360.com/images/headings/logo.gif http://www.law360.com/ http://www.law360.com/articles/134153 Teva Pharmaceuticals Ltd. has reportedly complained to the Federal Trade Commission that it has been unable to purchase bulk quantities of certain pharmaceuticals because brand-name drug companies are using a federal drug-safety program to unfairly limit competition. http://www.law360.com/articles/134153 http://www.law360.com/articles/129917 India and Brazil are reportedly on the verge of launching a formal complaint with the World Trade Organization as part of a long-simmering battle with the European Union over the frequent seizure of generic drugs at European ports over alleged patent violations. http://www.law360.com/articles/129917 http://www.law360.com/articles/126287 Oscient Pharmaceuticals Corp. and Ethypharm SA have dropped a patent infringement suit they brought against Lupin Ltd. over the cholesterol drug Antara, less than two weeks after Lupin announced that it had acquired the U.S. rights to Antara from bankrupt Oscient for nearly $39 million. http://www.law360.com/articles/126287 http://www.law360.com/articles/124595 Novartis AG and two generic-drug makers have agreed to dismiss without prejudice a total of four patent lawsuits in which the U.S. arm of the Switzerland-based pharmaceutical giant had said applications to make generic versions of the hypertension drug Lotrel infringed its patent. http://www.law360.com/articles/124595 http://www.law360.com/articles/122198 Albany Molecular Research Inc. has hit Dr. Reddy's Laboratories Inc. and Sandoz Inc. with a lawsuit, accusing the two of infringing a patent used in Sanofi-Aventis' Allegra. http://www.law360.com/articles/122198 http://www.law360.com/articles/116207 Orchid Chemicals & Pharmaceuticals Ltd. and its subsidiary Orgenus Pharma Inc. have reached an agreement with Schering-Plough Corp. that will allow Orchid to bring two generic versions of Schering's allergy drug Clarinex to the U.S. market in 2012. http://www.law360.com/articles/116207 http://www.law360.com/articles/115437 A battle is brewing between the European Union and India, which reportedly plans to complain to the World Trade Organization about the frequent seizure of Indian generic drugs at European ports over alleged patent violations. http://www.law360.com/articles/115437 http://www.law360.com/articles/103278 The defense of inequitable conduct needs reform, as the standard for proving the defense is perceived by many in the patent bar as being applied somewhat inconsistently right now at the Federal Circuit, says Joseph M. O’Malley Jr., chair of Paul Hastings Janofsky & Walker LLP's intellectual property practice. http://www.law360.com/articles/103278 http://www.law360.com/articles/101471 Teva Pharmaceutical Industries Ltd. has settled a lawsuit with Zydus Pharmaceuticals Inc. and Cadila Healthcare Ltd. over a patented process for making the key ingredient in the heart-failure treatment Coreg. http://www.law360.com/articles/101471 http://www.law360.com/articles/99862 Indian pharmaceutical company Wockhardt Inc. has fired back in a patent infringement suit over proposed generic versions of blockbuster sleep drug Lunesta, alleging that the drug’s maker, Sepracor Inc., deliberately misled the U.S. Patent and Trademark Office. http://www.law360.com/articles/99862 http://www.law360.com/articles/98260 Pharmaceutical company Sepracor Inc. has sued rival Mylan Inc. for seeking to make a generic version of Sepracor's insomnia drug Lunesta, which Sepracor claims would infringe its patents. http://www.law360.com/articles/98260 http://www.law360.com/articles/97828 Teva Pharmaceutical Industries Ltd. and Glenmark Pharmaceuticals Ltd. have agreed to dismiss claims and counterclaims of patent infringement and federal antitrust law violations in a lawsuit over two of Teva's patents related to congestive heart failure treatment Coreg. http://www.law360.com/articles/97828 http://www.law360.com/articles/96026 Mylan Pharmaceuticals Inc. and Schering Corp. have reached an agreement in patent litigation over Clarinex that will allow the generics maker to begin selling a copycat version of the allergy medicine in July 2012. http://www.law360.com/articles/96026 http://www.law360.com/articles/92979 Pharmaceutical company Sepracor Inc. has lodged a patent infringement suit against several companies, including Teva Pharmaceutical Industries Ltd. and Dr. Reddy's Laboratories Inc., that are seeking to make generic versions of the blockbuster sleep drug Lunesta. http://www.law360.com/articles/92979 http://www.law360.com/articles/92919 The Federal Trade Commission has disclosed that it will not challenge a so-called reverse payment agreement between generic-drug makers Mylan Inc., Dr. Reddy’s Laboratories Inc. and Cobalt Pharmaceuticals Inc. on one side and Keppra maker UCB SA on the other. http://www.law360.com/articles/92919 http://www.law360.com/articles/90553 As Merck & Co. prepares to join forces with Schering-Plough Co. in a $41.1 billion deal, the drugmaker stands ready to inherit a host of legal problems — including antitrust, employment, intellectual property and product liability suits — right along with an expanded arsenal of drugs and medical technology. http://www.law360.com/articles/90553 http://www.law360.com/articles/84698 Aventis Pharmaceuticals Inc. has taken another generics maker to court over a proposed generic version of the allergy drug Allegra. http://www.law360.com/articles/84698 http://www.law360.com/articles/82015 A patent covering the composition of Hoffmann-La Roche Inc.'s Boniva has now been dropped from all lawsuits seeking to stop generic companies from making their own version of the osteoporosis drug. http://www.law360.com/articles/82015 http://www.law360.com/articles/81145 Schering Corp., Sepracor Inc. and Dr. Reddy's Laboratories Ltd. have struck settlement deals that should resolve litigation and allow the India-based generics maker to enter the $362 million annual U.S. market for the allergy drug Clarinex in 2012, Dr. Reddy's said. http://www.law360.com/articles/81145 http://www.law360.com/articles/80679 Lupin Ltd. has become the latest company to settle patent litigation with Schering Corp. over a planned generic version of the allergy medication Clarinex. http://www.law360.com/articles/80679